BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26208777)

  • 1. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
    Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
    J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
    Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis.
    Wong JC; Chan HL; Tse YK; Yip TC; Wong VW; Wong GL
    Aliment Pharmacol Ther; 2017 Nov; 46(10):1001-1010. PubMed ID: 28940673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
    Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
    Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
    Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
    Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
    Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
    Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
    J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
    Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
    Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
    Hiramatsu N; Yamada R; Takehara T
    J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Lee TY; Hsu YC; Tseng HC; Yu SH; Lin JT; Wu MS; Wu CY
    JAMA Intern Med; 2019 May; 179(5):633-640. PubMed ID: 30882847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
    Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Tsan YT; Lee CH; Wang JD; Chen PC
    J Clin Oncol; 2012 Feb; 30(6):623-30. PubMed ID: 22271485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
    Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
    Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma.
    Wong GL; Tse YK; Chan HL; Yip TC; Tsoi KK; Wong VW
    Aliment Pharmacol Ther; 2016 Apr; 43(7):802-13. PubMed ID: 26843444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.